I, and C4BP as well as all primary antibodies (anti C1q, A200/3b; anti C2,
A212/18b; anti C3, A213/5a; anti C4, A201/3a; anti factor H, A237/4) were
purchased from Complement Technology. Recombinant ApoE isoforms from BioCat;
plasma-purified ApoE3 from Biopure. ApoE peptides were generated by Peptide 2.0:
ApoE 30-40 LGRFWDYLRWV; ApoE 75-85 YKSELEEQLTPV; ApoE 139-152 SHLRKLRKRLLRDA;
ApoE 210-232 WGERLRARMEEMGSRTRDRLDEV. LDL and malondialdehyde-modified LDL
(MDA-LDL) were from Cell Biolabs, copper oxidized LDL (oxLDL) from Thermo Fisher
(L34357), ApoA from Athens Research&Technology, vitronectin (Vnt) from
Corning. Aβ and Aβ fibrils from GenSript. Recombinant EfB was
expressed as described65 . Additional
antisera used were: anti-C5b-9 (clone AE11-MO777-Dako), anti C1s
(11951-05011-AssaybioTch), anti ApoE ((178479-Calbiochem), anti ApoE (Merck,
178479), anti LDLR (HB04JL2204-B-SinoBiological), anti Aβ (clone
32A1-Abfrontier), anti goat IgG (13C0836-Sigma Aldrich) and anti rabbit IgG
(13C0529-Sima Aldrich), IgM (120228-Jackson ImmunoResearch Laboratories).